Preparing for Close-Out of Studies and Sites

Similar documents
10/17/2016. Learning Objectives. What is Drug Accountability. Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP

Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

Guidelines for Setting Up a Regulatory Binder

Regulatory Binder: Set-up and Maintenance

1 The Clinical Research Coordinator (CRC)... 1

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office

Regulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005

Compliance and Quality Monitoring: What, Why, When, and How

FDA Sponsor and Investigator Responsibility Checklist

Clinical Trial Performance Metrics

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

Source Documents and Regulatory Binders October 6, 2016

Source And Regulatory Documentation for DMID Clinical Studies

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

and Study Initiation

and Study Initiation

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices

Standard Operating Procedures Guidelines for Good Clinical Practice

Implementing Good Clinical Practice at an Academic Research Institution

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Introduction to Clinical Research

Investigator Site File Index (CTIMP)

Regulatory Binder Guidance

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies

SELF-ASSESSMENT CHECKLIST

Stephanie Gentilin, CCRA

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder

Compliance Program Guidance Manuals (CPGMs) -1-

ELEMENTS OF A DATA MONITORING PLAN

1. POLICY STATEMENT: 2. BACKGROUND:

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

St. Luke s University Health Network

Drug Accountability. Kevin E. Anger PharmD, BCPS Manager Investigational Drug Services Brigham and Women s Hospital

Investigator Site File Index (Medical Devices)

INVESTIGATIONAL PRODUCT ACCOUNTABILITY, STORAGE, DISPENSING, TRANSPORT AND RETURN

OCTC 2012 CRO Selection

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016

Louise Brook Clinical Trials Quality Monitor. Date

Standard Operating Procedure for Archiving

Trial Services. The allround trial specialist in cardiology Leading since cardialysis.com

Standard Operating Procedure

Sponsor-Investigator Responsibilities In Clinical Trials

PHARMACY, MEDICINES & POISONS BOARD

Study Files and Filing

ARCHIVING REGULATIONS

11.0 FDA-Regulated Research

Index of Standard Operating Procedures for all research Sponsored by the UHL

PREP Workshop # 20: Investigational Drug Accountability. Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS

STUDY CLOSURE AND ARCHIVING

Vanessa Laroche, CCRC, CCRA, CIP, CQA Quality Assurance Specialist Technical Resources International (TRI), Inc.

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

INVESTIGATIONAL DRUG MANAGEMENT OVERVIEW

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

CDISC Standards: Current and Future

FDA Audit Preparation

National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services

Once notified of the end of trial, a Research Manager, on behalf of the Sponsor, will contact the CI to arrange a close down monitoring visit.

STUDY REQUEST FORM AND TRAQ DSS FORM

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

STANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE

Index of Standard Operating Procedures for all research Sponsored by the UHL

TITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17

Trial Master File. SOP No. SOP 7

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

Views of a Clinical Study Report

End of Study Notification, Close-Out and Reporting Sponsored Research. Noclor/Spon/S11/01. SOP Reference ID:

Aldrey Oliveira June 2nd 2016 Rio de Janeiro - Brazil

NN DM 1002 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR DATA MANAGEMENT PLAN DEVELOPMENT SOP: NN DM 1002 Version No: 2.0 Effective Date: 21Oct20

Guidance on Requirements of the Sponsor and the Investigator as a Sponsor

I. Purpose. II. Definitions. Last Approval Date

The purpose of these guidelines is to describe a standardized approach for the management of

Sponsor/Investigator Responsibilities

Show Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH

Presentation of Capabilities Reverse Logistics

Clinical Data Management Services

UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities

Human Research Protection Program Policy

Investigator s Responsibility

FDA Audit Preparation

Meeting sponsor s criteria : strategy to collaborate, engage and deliver

STANDARD OPERATING PROCEDURE

The Right Prescription for Working with Investigational Drug Service at BMC

Investigator-Initiated INDs

Transcription:

Preparing for Close-Out of Studies and Sites Presented by: Christie Thomas, MPH, CCRA Matthew Wright, BS, CCRP Dikla Blumberg, PhD CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training has been funded in whole or in part with federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under Contract No.HHSN271201000024C

Learning Objectives Discuss planning for trial close-out, and identify critical activities that make for timely and efficient close-out. Define roles and responsibilities, regulatory obligations, documentation requirements, and other processes to consider at the end of a study. Review lessons learned in the close-out of other CTN studies. 2

3

Why It Matters Regulatory obligation Resources invested Ability to answer research question Contribution to generalizable knowledge and improved care It s our job 4

Key Personnel Involved Research Site (RA, RC, Medical Staff, PI) Regional Research & Training Center (RRTC) (Local QA, PM, PD, LI) Clinical Coordinating Center (CCC) and Data and Statistics Center (DSC) (Protocol Specialist, CCC Monitor, Medical Monitor, Safety Monitor, Data Manager, Statistician) Other External Partners (Vendors, Central Laboratory, Central Pharmacy, Suppliers, Regulatory Entities) 5

Timeline from Development to Study Start Protocol Reviews: PRB, DSMB, Lead Node IRB Approval Site Selection Other Regulatory Submission(s) Revise ecrfs at DM meeting Then, revise Ops Manual as needed (recruitment materials, logs et. al.) Selected Sites Hiring Staff Initiation Visits (Node QA/CCC) Site Endorsements Start Enrollment 4 wks before study start Dev t Protocol Approval Trial Dev & Logist. DM Meeting Nat l Training Study Start 6-8 wks before nat l trng CCTN Concept Approval CTN Number assigned Initial Budget/revise as needed Timeline Development Other Study Docs in Dev t: ecrfs, Ops Manual, QA Plan, SOPs Training Dev & Planning Meds, Labs, and Supplies Contracts Sites to submit for IRB Approval Training Doc Form Delegation Log Regulatory Training/Document Collection Supplies/Meds to sites Allen, C., Jelstrom, E., & Kropp, F. (2013). CTN webinar: Getting multi-site trials up and running on time. Retrieved from http://ctndisseminationlibrary.org/display/1034.htm. 6

Timeline from Study Start to Close-Out 4 months after database lock 18 months after database lock Study Start End of Enrollment Last Pt Last Visit Database Lock Final Report Primary Paper Data Share 2 months after LPLV* 6 months after database lock *LPLV Last Participant Last Visit 10

Components of Site Close-Out Storage & Record Retention Data Cleaning Monitoring Visits Safety & Regulatory Study Personnel Medication, Supplies & Equipment Campanella, M. (2013). CTN Webinar: Site close-out An overview. Retrieved from http://ctndisseminationlibrary.org/display/974.htm. 11

CTN Site Close-Out Checklist 13

SAFETY & REGULATORY

Safety and Regulatory Adverse Event Reporting All AEs/SAEs that require reporting must be entered in AdvantageEDC and reported to the IRB, as appropriate. AEs must be resolved prior to site closure: Resolved without sequelae Resolved with sequelae Resolved by convention 16

Safety and Regulatory Protocol Deviation (PD) Reporting All PDs in AdvantageEDC must be complete and resolved prior to site closure PDs that require IRB reporting must have a corresponding date of report NIDA CCC Protocol Specialist will consult with the Lead Node to perform PD cleaning prior to close-out and may request edits 17

Safety and Regulatory Regulatory Binder/Files must be complete and copies of all required documents uploaded to the Regulatory Tracking System (RTS) IRB-approved protocols IRB-approved consent forms* Protocol Signature Pages * Form FDA 1572 / IA* Final Staff Delegation Log (signed by PI)* HSP and GCP Training Certifications* CVs (for anyone listed on the 1572/IA) Licenses, if applicable* Financial Disclosure Certification (IND trials)* Training Documentation Form* IRB approval letters* Copies of other participant agreement documents (HIPAA auth, CA Bill of Rights, W-9, ROIs, etc) IRB Notification of Study Closure* Active FWA DEA Registrations* Site Visit Log SOPs * Required to be submitted to the CCC via RTS 18

Safety and Regulatory Prior to close-out, a NIDA CCC Protocol Specialist will provide a RTS audit report of documents housed in the system Any action items should be resolved prior to site close-out 19

Sample RTS Audit Report Site Documents 20

Safety and Regulatory For IND trials, the original, signed copy of all Form FDA 1572s must be mailed to the CCC (or the IND holder if other than the sponsor) For non-ind trials, the Investigator Agreement should be signed, dated, and mailed to the CCC IND Investigational New Drug application 21

Safety and Regulatory Some tasks may not be completed until after database lock has occurred Final Staff Delegation Log with PI signature IRB acknowledgement of study closure Final Site Close-Out Checklist (These tasks will be listed as action items on the site visit report) 22

QA & MONITORING

Close-Out Monitoring Visits Sites participating in trials within the CTN typically have 2 close-out visits Local QA (RRTC) NIDA CCC (Emmes) Items covered during close-out visit: Action items from the last monitoring visit Data integrity/query resolution Roles and responsibilities Record storage requirements Disposition of supplies / study medication Regulatory requirements Publications Review of close-out presentation 24

Close-Out Monitoring Visits (cont.) Close-Out visit may not occur until last participant last visit has occurred Ideally, the final local QA monitoring visit will occur before the CCC close-out visit, but this is not required CCC close-out visits can either be done on-site or remotely by conference call At a minimum, the Site PI and a SC/RA must be present NIDA CCC will provide Close-Out Memo 25

STUDY PERSONNEL

Close-Out of Study Personnel Updated CTN Research Staff Information Forms should be sent to the DSC Help Desk for any staff no longer participating in the study Staff members that continue to perform study functions (i.e., those that use AdvantageEDC for data cleaning purposes or RTS for regulatory uploads) should not send this form until after database lock Staff Information Form can be found on Livelink LiveLink: https://livelink.nida.nih.gov Or contact the DSC Help Desk: nidadsc2help@emmes.com 27

Break for Questions Use the chat to post questions or comments 28

MEDICATION, SUPPLIES, & EQUIPMENT

Medication Determine who has Disposition Authority Should be indicated in the Site Close-Out Checklist Is generally the same source that provided the medication If study Investigational Product is being returned to the central pharmacy, they or the CCC will provide detailed instructions Final drug reconciliation is a key process at close-out 30

Supplies & Equipment Work with CCC to maintain a low supply inventory toward the end of the study Consider who provisioned the supplies and equipment, namely who owns it, then ask when is it returned and how? This information is indicated on the Site Close-Out Checklist 31

Supplies & Equipment (cont.) Items that may be donated: Urine collection and testing supplies, pregnancy tests Lab kits, needles, shipping boxes/gel packs Items that must be destroyed: Prescription labels, medication wallet cards, waybills Any expired supplies that are not returned Items that must be returned: Genetics kits- to NIDA repository Contact Node regarding: Gloves, band aids, equipment (e.g., refrigerator), office supplies, computers 32

DATA CLEANING ACTIVITIES

Data Cleaning Activities Data Managers (Data and Statistics Center (DSC) at Emmes) Generate data quality reports, missing form and value reports and integrity checks throughout the study and at close-out It s vital to maintain complete and accurate data throughout the trial Can check data completion via Missing Forms and Missing Values Reports 34

Data Cleaning Activities (cont.) Complete all exception requests (out of range items, missing value or missing form exceptions) as needed End of Study Forms submitted and signed by PI Access the Monitoring Discrepancy reports in EDC frequently and resolve all data discrepancies Be responsive to requests from the DSC! 35

RECORDS RETENTION & STORAGE

Records Retention & Storage Sites should establish procedures for the archiving of research records, in compliance with state, local, institutional, and IRB regulations At minimum, study records for CTN studies must be maintained for 3 years after database lock CTN Policies and Procedures Section 8.3 38

Records Retention & Storage (cont.) RRTC prepares clear, written documentation of the location and the retrieval process for research records for a given site and informs the Lead Team and the CCC at study close-out Must include a contact person Must notify if storage location changes Must notify prior to the destruction of any protocol related records CTN Policies and Procedures Section 8.3 39

WRAPPING IT UP! 40

In Summary Preparation for an efficient close-out begins before the study starts Careful and timely execution of all trial-related duties throughout the implementation phase will aid the close-out process Appropriate site staff (including the PI) must be available through (and beyond) database lock Utilize available tools and resources If you do not know, please ask for help 41

References Allen, C., Jelstrom, E., & Kropp, F. (2013). CTN webinar: Getting multi-site trials up and running on time. Retrieved from http://ctndisseminationlibrary.org/display/1034.htm. Campanella, M. (2013). CTN Webinar: Site Close-Out An overview. Retrieved from http://ctndisseminationlibrary.org/display/974.htm. ICH Efficacy Guidelines - E6 Good Clinical Practice. (1996). Retrieved from http://www.ich.org/fileadmin/public_web_site/ ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. NIDA CTN Policies and Procedures Guide (v 5.0). Retrieved from http://www.ctndsc2.com/. Reference any Institutional/Local IRB Policies and Procedures 42

Questions / Comments Alternatively, questions can be directed to the presenter(s) by sending an email to CTNtraining@emmes.com. 43

http://ctndisseminationlibrary.org A copy of this presentation will be available electronically. 44

Survey Reminder All participants are encouraged to complete the post webinar survey, which will be issued directly following this webinar session. This is the primary collective tool for rating your experience with this training and for communicating the interests and needs of CTN members and associates. 46

THANK YOU FOR YOUR PARTICIPATION